Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Inclusion Criteria: * Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma * Progressed or not tolerated standard therapy, and no further standard therapy is available * Archival and screening tumor biopsy * Eastern Cooperative Oncology Group Performance Status: 0 or 1 * Adequate organ function Exclusion Criteria: * Prior cancer-directed modalities or investigational drugs within 4 wks or 5 half lives, whichever is shorter * Symptomatic brain metastases (prior treatment and stable metastases are allowed) * Acute or chronic renal disease or pancreatitis * Diarrhea ≥ Grade 2, impaired gastrointestinal absorption * Impaired cardiac function * History of diabetes requiring treatment, glucose \>126 mg/dL, Glycated hemoglobin (HbA1c) ≥6.5% * Peripheral neuropathy ≥ Grade 2 * Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer) * Pregnant, inadequate contraception, breast feeding * Most concurrent second malignancies * Part B only: Prior treatment with agents targeting both mammalian target of rapamycin (mTOR) complexes (dual mammalian target of rapamycin complex 1/2 inhibitors) and/or PI3K/AKT pathways. However, prior treatment with isolated target of rapamycin complex 1 (TORC1) inhibitors (eg., rapalogs) is allowed in both parts of this study.